The distribution of the third approved vaccine for emergency use in the United States begins on Tuesday.
According to a senior administration official, about 4 million doses of Johnson & Johnson vaccine will be available from Tuesday morning alongside two previously approved vaccines, those of Pfizer / BioNTech and Moderna.
The Johnson & Johnson vaccine was eagerly awaited by U.S. health officials mainly because it is used in a single dose. But officials have urged Americans to get whatever vaccine is available to them, reiterating that all three are safe and effective. According to data from a study that included three continents, the Johnson & Johnson vaccine is 85% effective against serious illness, hospitalization and deaths from COVID.
It also offers protection in countries where the South African variant is spreading. Johnson & Johnson is also seeking authorization to use the vaccine in Europe and from the World Health Organization. Since the start of the pandemic, some 28.6 million Americans have been infected with COVID-19 and more than 513,000 have lost their lives.
Meanwhile an international study shows that in some countries there is an increasing trend for getting the vaccine. A study by Text CNC shows that 89% of Britons are now pro-vaccinated, up from 65% in September last year. In Sweden 76 percent are in favor, compared to 51 percent in September. According to the study, 68 percent of men worldwide support vaccination, but among women this figure is lower, 55 percent.